Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04942301 | PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy | unknown | Phase 1 | 24 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 30, 2021 | clinicaltrials |
| NCT01711697 | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 16 | Emory UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT04890795 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 237 | Advenchen Laboratories Nanjing Ltd.INDUSTRY | 1 | May 18, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | unknown | Phase 1 / Phase 2 | 96 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | unknown | Phase 1 | 42 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03227016 | Study in Patients With SCLC of Veliparib in Combination With Topotecan | unknown | Phase 1 | 30 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04390984 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | unknown | Phase 1 | 22 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04448379 | Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 | 48 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04667975 | The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy(CKD-702) | unknown | Phase 1 | 74 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT04659785 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | unknown | Phase 1 / Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04487093 | Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04273815 | A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | unknown | Phase 1 / Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT03987867 | Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04193098 | Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC | unknown | Phase 1 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04397926 | Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04413227 | A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04404543 | A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer | unknown | Phase 1 | 71 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | May 27, 2020 | clinicaltrials |
| NCT04153799 | Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 | 11 | Sun Yat-sen UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT03706287 | Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC | unknown | Phase 1 / Phase 2 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT04333004 | Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With Chemotherapy | unknown | Phase 1 / Phase 2 | 40 | Xiaorong DongOTHER | 0 | Apr 3, 2020 | clinicaltrials |
| NCT03130881 | Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC. | unknown | Phase 1 | 60 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04175158 | Clinical Trial in Chinese Healthy Volunteers of GB222 | unknown | Phase 1 | 84 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT03910127 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | unknown | Phase 1 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT03396497 | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | unknown | Phase 1 | 17 | Lycera Corp.INDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT04059874 | Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate | unknown | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03971214 | PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer(PICARES) | unknown | Phase 1 | 6 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03903887 | A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | unknown | Phase 1 | 30 | Shenzhen People's HospitalOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT02956551 | Personalized DC Vaccine for Lung Cancer(SKLB1608) | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT03527251 | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC(SEQUENCE) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03525782 | Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC | unknown | Phase 1 / Phase 2 | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Jun 30, 2021source: clinicaltrials